156 results on '"Candiota, Ana Paula"'
Search Results
2. Tracking Therapy Response in Glioblastoma Using 1D Convolutional Neural Networks
3. Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction
4. Platinum-Based Nanoformulations for Glioblastoma Treatment: The Resurgence of Platinum Drugs?
5. Platinum-based nanoformulations for glioblastoma treatment: the resurgence of platinum drugs?
6. Metal-Free Radical Dendrimers as MRI Contrast Agents for Glioblastoma Diagnosis: Ex Vivo and In Vivo Approaches
7. Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice.
8. Proximity Mapping of CCP6 Reveals Its Association with Centrosome Organization and Cilium Assembly
9. Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?
10. Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation
11. Protein Kinase CK2 Content in GL261 Mouse Glioblastoma
12. Synthesis and Validation of a Bioinspired Catechol-Functionalized Pt(IV) Prodrug for Preclinical Intranasal Glioblastoma Treatment
13. Intranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy
14. Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?
15. Metal-Free Radical Dendrimers as MRI Contrast Agents for Glioblastoma Diagnosis: Ex Vivo and In Vivo Approaches
16. Intranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy
17. Establishing Imaging Biomarkers of Host Immune System Efficacy during Glioblastoma Therapy Response: Challenges, Obstacles and Future Perspectives
18. Incremental Gaussian Discriminant Analysis based on Graybill and Deal weighted combination of estimators for brain tumour diagnosis
19. Ex vivo assessment of polyol coated-iron oxide nanoparticles for MRI diagnosis applications: toxicological and MRI contrast enhancement effects
20. In Vivo and Ex Vivo Magnetic Resonance Spectroscopy of the Infarct and the Subventricular Zone in Experimental Stroke
21. Conservation of aging and cancer epigenetic signatures across human and mouse
22. Conservation of aging and cancer epigenetic signatures across human and mouse
23. Minimization of spectral pattern changes during HRMAS experiments at 37 degrees celsius by prior focused microwave irradiation
24. Bioinspired Theranostic Coordination Polymer Nanoparticles for Intranasal Dopamine Replacement in Parkinson’s Disease
25. Conservation of Aging and Cancer Epigenetic Signatures across Human and Mouse
26. Short-term temperature effect on the HRMAS spectra of human brain tumor biopsies and their pattern recognition analysis
27. Multiproject–multicenter evaluation of automatic brain tumor classification by magnetic resonance spectroscopy
28. Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches
29. In Vivo Magnetic Resonance Spectroscopic Imaging and Ex Vivo Quantitative Neuropathology by High Resolution Magic Angle Spinning Proton Magnetic Resonance Spectroscopy
30. Interpreting response to TMZ therapy in murine GL261 glioblastoma by combining Radiomics, Convex-NMF and feature selection in MRI/MRSI data analysis
31. Robust Conditional Independence maps of single-voxel Magnetic Resonance Spectra to elucidate associations between brain tumours and metabolites
32. Anti‐tumour immune response in GL261 glioblastoma generated by Temozolomide Immune‐Enhancing Metronomic Schedule monitored with MRSI‐based nosological images
33. Embedding MRI information into MRSI data source extraction improves brain tumour delineation in animal models
34. Cancer metabolism in a snapshot: MRS(I)
35. Dual T1/ T2 nanoscale coordination polymers as novel contrast agents for MRI: A preclinical study for brain tumor
36. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide
37. Brain metabolic pattern analysis using a magnetic resonance spectra classification software in experimental stroke
38. Improving Ribosomal RNA Integrity in Surgically Resected Human Brain Tumor Biopsies
39. Protein Kinase CK2 Content in GL261 Mouse Glioblastoma
40. r1andr2Relaxivities of Dendrons Based on a OEG-DTPA Architecture: Effect of Gd3+Placement and Dendron Functionalization
41. Robustness of Equations that Define Molecular Subtypes of Glioblastoma Tumors Based on Five Transcripts Measured by RT-PCR
42. A new ex vivo method to evaluate the performance of candidate MRI contrast agents: A proof-of-concept study
43. Electronic supplementary material for A new ex vivo method to evaluate the performance of candidate MRI contrast agents: A proof-of-concept study
44. Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment.
45. Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.
46. Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma
47. A new ex vivo method to evaluate the performance of candidate MRI contrast agents: a proof-of-concept study
48. DCE@urLAB: a dynamic contrast-enhanced MRI pharmacokinetic analysis tool for preclinical data
49. Incremental gaussian discriminant analysis based on graybill and deal weighted combination of estimators for brain tumour diagnosis
50. Development of a predictor for human brain tumors based on gene expression values obtained from two types of microarray technologies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.